Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting ageing men in Singapore, yet it remains poorly understood by many who experience it. It is not a form of cancer, but it can significantly disrupt sleep, work and quality of life through its effect on urination. As Singapore's population ages, more men are presenting to clinics with symptoms that they had quietly tolerated for years, often assuming that slower urination or frequent night-time trips to the toilet were simply an inevitable part of getting older.
Understanding the anatomy behind BPH, how doctors measure its severity, and what treatment options exist can help men make informed decisions rather than suffering in silence or waiting until symptoms become severe.
Prostate anatomy and why enlargement causes symptoms
The prostate is a gland roughly the size of a walnut that sits just below the bladder, surrounding the urethra, the tube through which urine passes out of the body. Its main job is producing seminal fluid that nourishes and transports sperm. In younger men the prostate stays relatively small and does not interfere with urination.
As men age, hormonal changes, particularly the local conversion of testosterone into dihydrotestosterone (DHT), stimulate the growth of prostate tissue. This growth typically begins in the transition zone, the part of the gland closest to the urethra. As this zone enlarges, it compresses and narrows the urethral channel, similar to how a garden hose pinches when squeezed. The bladder muscle has to work harder to push urine through this narrowed passage, which over time leads to the constellation of symptoms known as lower urinary tract symptoms, or LUTS.
Studies suggest that roughly 10 percent of men in their 30s already show histological evidence of BPH, and prevalence rises sharply with age, affecting more than 40 percent of men in their 50s and over 65 percent of men by their 70s. This means that most men who live long enough will develop some degree of prostate enlargement, though not all will develop bothersome symptoms.
Understanding LUTS and the IPSS score
Lower urinary tract symptoms are typically divided into two categories:
Voiding (obstructive) symptoms occur because urine flow is being physically blocked:
- Weak or slow urinary stream
- Difficulty starting urination (hesitancy)
- Straining to pass urine
- Intermittent stream that stops and starts
- A sense of incomplete bladder emptying
Storage (irritative) symptoms occur because the bladder becomes overactive from having to work harder:
- Frequent urination during the day
- Urgency, or a sudden strong need to urinate
- Nocturia, or waking multiple times at night to urinate
- Occasional urge incontinence
To quantify symptom severity in a standardised way, doctors use the International Prostate Symptom Score (IPSS), a validated questionnaire consisting of seven questions about urinary symptoms plus one question about quality of life. Each symptom is scored from 0 to 5 based on frequency, giving a total score out of 35.
| IPSS score range | Symptom severity | Typical approach |
|---|---|---|
| 0-7 | Mild | Lifestyle changes, monitoring |
| 8-19 | Moderate | Medical therapy usually recommended |
| 20-35 | Severe | Medical therapy, consider procedures if not responsive |
The IPSS is useful because, as many men are surprised to learn, the severity of symptoms does not correlate closely with prostate size. Some men with only mildly enlarged prostates report severe symptoms, while others with substantially enlarged glands report minimal bother. This is one reason self-diagnosis based on "how bad it feels" is unreliable, and a proper assessment matters.
Differential diagnosis: it is not always BPH
Because urinary symptoms can arise from several different conditions, a doctor's role is partly to rule out other causes before attributing symptoms to BPH.
Prostatitis is inflammation or infection of the prostate gland, which can cause similar voiding symptoms but often comes with pelvic pain, fever, or discomfort during ejaculation. Unlike BPH, prostatitis can affect younger men and may present acutely. A digital rectal exam typically reveals a tender, sometimes boggy prostate rather than the firm, smoothly enlarged gland typical of BPH.
Prostate cancer can also cause urinary symptoms, particularly in more advanced stages, though early prostate cancer is often silent. Because BPH and prostate cancer can coexist in the same gland, any middle-aged man presenting with urinary symptoms should also be screened appropriately, especially if he has risk factors such as family history. Prostate cancer screening with PSA blood testing and clinical examination remains an essential part of the workup for LUTS, not an optional extra.
Overactive bladder (OAB) is a condition of the bladder itself, rather than the prostate, causing urgency and frequency without necessarily impairing flow. OAB can occur independently or alongside BPH, and distinguishing between the two matters because treatment differs; anticholinergic or beta-3 agonist medications for OAB do not address prostatic obstruction, and alpha blockers for BPH do not fully resolve isolated bladder overactivity.
Urethral stricture, bladder stones, and neurological conditions affecting bladder nerve control can also mimic BPH symptoms and need to be considered, particularly in men with a history of trauma, prior surgery, or diabetes.
Investigations: how BPH is diagnosed
A thorough evaluation typically involves several components working together, rather than relying on a single test.
History and IPSS questionnaire establish the nature, duration and severity of symptoms, along with their impact on daily life and sleep.
Digital rectal examination (DRE) allows the doctor to assess prostate size, texture and symmetry. A smooth, uniformly enlarged, non-tender gland is typical of BPH, whereas hard nodules or asymmetry raise suspicion for cancer.
PSA blood test measures prostate-specific antigen, a protein that can be elevated in BPH, prostatitis, and prostate cancer alike. PSA alone cannot distinguish between these conditions, but combined with DRE findings and clinical context, it helps guide further testing and risk stratification.
Uroflowmetry is a simple, non-invasive test where the patient urinates into a specialised device that measures flow rate over time. A reduced maximum flow rate supports a diagnosis of obstruction and can help track response to treatment.
Post-void residual (PVR) measurement, usually done via bladder ultrasound immediately after urination, checks how much urine remains in the bladder. A high residual volume suggests significant obstruction and raises concern about potential kidney impact if left untreated.
Ultrasound of the prostate, bladder and kidneys provides an estimate of prostate volume, screens for bladder stones, evaluates bladder wall thickening from chronic strain, and checks whether the kidneys show any signs of back-pressure from long-standing obstruction.
In select cases, urodynamic studies or cystoscopy may be recommended for more complex presentations, but for most men, the combination above provides sufficient information to guide treatment decisions.
Medical treatment options
For men with mild to moderate symptoms, medication is usually the first line of treatment, and many men achieve good symptom control without ever needing a procedure.
Alpha blockers (such as tamsulosin, alfuzosin or silodosin) relax the smooth muscle in the prostate and bladder neck, improving urine flow relatively quickly, often within days to weeks. They do not shrink the prostate but relieve the functional obstruction. Common side effects include dizziness, low blood pressure on standing, and retrograde ejaculation (where semen enters the bladder instead of exiting normally during ejaculation).
5-alpha reductase inhibitors (5-ARIs), such as finasteride and dutasteride, work differently by blocking the conversion of testosterone to DHT, gradually shrinking the prostate over months. They are most useful for men with significantly enlarged prostates and take three to six months to show full effect. Sexual side effects are more notable with this class, including reduced libido, erectile difficulties, and reduced ejaculate volume in a proportion of users; these effects are usually reversible on stopping the medication, though some men report persistent changes.
Tadalafil, more widely known as a treatment for erectile dysfunction, is also HSA-approved at a low daily dose specifically for BPH symptoms. It works by relaxing smooth muscle in the prostate and bladder and improving blood flow. This makes it an appealing option for men who have both LUTS and erectile dysfunction, addressing two concerns with a single daily tablet.
Combination therapy, typically an alpha blocker plus a 5-ARI, is often used for men with larger prostates and more severe symptoms, as studies show combination treatment reduces the risk of symptom progression and the need for surgery more effectively than either drug alone.
| Medication class | Onset of action | Best suited for | Key sexual side effects |
|---|---|---|---|
| Alpha blockers | Days to weeks | Rapid symptom relief, any prostate size | Retrograde ejaculation |
| 5-ARIs | 3-6 months | Larger prostates, long-term shrinkage | Reduced libido, ED |
| Tadalafil (low dose) | Days to weeks | LUTS with coexisting ED | Generally favourable |
| Combination therapy | Weeks to months | Larger prostates, higher symptom scores | Combined profile above |
Procedural and surgical treatment
When medications fail to control symptoms adequately, or when complications develop such as recurrent urinary retention, bladder stones, recurrent infections or kidney impairment, procedural treatment becomes appropriate.
Transurethral resection of the prostate (TURP) remains the long-standing surgical benchmark, involving removal of obstructing prostate tissue through the urethra without external incisions. Newer minimally invasive options, including laser enucleation and vaporisation techniques, water vapour thermal therapy, and prostatic urethral lift, offer alternatives with different recovery profiles and varying effects on ejaculatory function. The right choice depends on prostate size, symptom severity, patient fitness, and personal priorities, particularly around preserving sexual function, which should always be discussed candidly with the treating doctor.
Living with BPH: practical measures
Alongside medical treatment, simple lifestyle adjustments can meaningfully reduce symptom burden. Reducing evening fluid intake, moderating caffeine and alcohol, avoiding prolonged sitting, treating constipation, and staying physically active all support bladder health. Men on multiple medications for other conditions should also review these with their doctor, since certain decongestants and antihistamines can worsen urinary retention.
Given the overlap between BPH, sexual health, and general metabolic health, many men benefit from a broader health screening that also checks testosterone levels, blood sugar, and cardiovascular risk factors, since these often influence both prostate and urinary symptoms.
Common questions
Does BPH increase the risk of prostate cancer?
BPH itself does not turn into prostate cancer, but both conditions become more common with age and can coexist in the same gland. This is why PSA testing and clinical examination remain important even when symptoms seem clearly related to enlargement rather than malignancy.
Can BPH be managed without medication?
Mild symptoms with a low IPSS score can often be managed with lifestyle changes alone, including fluid timing and avoiding bladder irritants. However, regular monitoring is still recommended since symptoms can progress gradually over time.
Will alpha blockers or 5-ARIs affect my sex life permanently?
Sexual side effects such as retrograde ejaculation with alpha blockers or reduced libido with 5-ARIs are generally reversible once the medication is stopped, though a small proportion of men report symptoms persisting longer. Discussing this openly with your doctor before starting treatment helps set realistic expectations.
How is BPH different from an overactive bladder?
BPH originates from physical obstruction caused by prostate enlargement, while overactive bladder is a separate condition involving involuntary bladder muscle contractions. The two can occur together, and proper diagnosis with uroflowmetry and post-void residual testing helps determine which is the dominant driver of symptoms.
When should I see a doctor about urinary symptoms?
Any new or worsening urinary symptoms, particularly frequent night-time urination, weak stream, or a sense of incomplete emptying, warrant an evaluation, especially in men over 45. Sudden inability to urinate is a medical emergency requiring immediate attention.
What does a consultation for BPH involve?
A typical consultation at Hisential costs from S$50 after GST and includes a detailed history, IPSS scoring, and discussion of whether further tests such as PSA, uroflowmetry or ultrasound are needed. Our SMC-registered doctors can then recommend an appropriate treatment plan, which you can arrange through booking an appointment or by learning more about our doctors.
Benign Prostatic Hyperplasia (BPH)
Frequent night-time urination, weak stream, hesitancy - common after 50 and almost always treatable.
Read about Benign Prostatic Hyperplasia (BPH)